Autolus Therapeutics plc (NASDAQ:AUTL) Sees Significant Growth in Short Interest

Autolus Therapeutics plc (NASDAQ:AUTL) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 8,630,000 shares, a growth of 12.4% from the December 31st total of 7,680,000 shares. Based on an average daily trading volume, of 1,830,000 shares, the short-interest ratio is presently 4.7 days.

Autolus Therapeutics Stock Down 3.8 %

Shares of NASDAQ AUTL traded down $0.09 during midday trading on Monday, hitting $2.13. 681,467 shares of the company’s stock were exchanged, compared to its average volume of 1,087,673. The firm has a market capitalization of $565.45 million, a PE ratio of -1.76 and a beta of 2.05. Autolus Therapeutics has a 12 month low of $2.07 and a 12 month high of $7.37. The company’s 50 day moving average price is $2.53 and its 200 day moving average price is $3.43.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the previous year, the business posted ($0.26) EPS. On average, equities research analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AUTL. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $10.40.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds have recently bought and sold shares of AUTL. Dumont & Blake Investment Advisors LLC bought a new position in shares of Autolus Therapeutics during the fourth quarter worth approximately $35,000. ProShare Advisors LLC bought a new position in Autolus Therapeutics during the 2nd quarter worth $43,000. Arkadios Wealth Advisors acquired a new stake in shares of Autolus Therapeutics during the fourth quarter worth $47,000. Capstone Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics in the third quarter valued at about $51,000. Finally, Avanza Fonder AB acquired a new position in shares of Autolus Therapeutics in the fourth quarter valued at about $75,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.